Orchestra BioMed’s (OBIO) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Orchestra BioMed (NASDAQ:OBIO) in a research note released on Friday morning,Benzinga reports. HC Wainwright currently has a $14.00 price objective on the stock. HC Wainwright also issued estimates for Orchestra BioMed’s Q4 2024 earnings at ($0.42) EPS, FY2024 earnings at ($1.65) EPS, Q1 2025 earnings at ($0.42) EPS, Q2 2025 earnings at ($0.43) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.44) EPS and FY2025 earnings at ($1.72) EPS.

Other equities analysts also recently issued research reports about the stock. B. Riley began coverage on shares of Orchestra BioMed in a research note on Thursday, July 25th. They set a “buy” rating and a $15.00 price objective on the stock. Chardan Capital reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Orchestra BioMed in a research report on Wednesday, November 13th.

Orchestra BioMed Stock Down 0.2 %

Shares of NASDAQ OBIO opened at $5.83 on Friday. The stock has a market capitalization of $221.60 million, a price-to-earnings ratio of -3.62 and a beta of 0.42. Orchestra BioMed has a 52 week low of $4.22 and a 52 week high of $11.69. The firm has a 50-day moving average price of $5.42 and a 200 day moving average price of $6.27.

Orchestra BioMed (NASDAQ:OBIO) last posted its earnings results on Tuesday, November 12th. The company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.03. The company had revenue of $0.99 million for the quarter, compared to the consensus estimate of $0.81 million. Orchestra BioMed had a negative return on equity of 107.04% and a negative net margin of 2,179.33%. Equities research analysts expect that Orchestra BioMed will post -1.67 EPS for the current fiscal year.

Insider Activity at Orchestra BioMed

In related news, insider Darren Sherman sold 6,804 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $5.48, for a total value of $37,285.92. Following the sale, the insider now directly owns 772,691 shares in the company, valued at $4,234,346.68. This trade represents a 0.87 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 24,260 shares of company stock valued at $138,573 in the last quarter. Insiders own 6.70% of the company’s stock.

Institutional Investors Weigh In On Orchestra BioMed

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new position in shares of Orchestra BioMed in the 3rd quarter worth approximately $52,000. ABLE Financial Group LLC purchased a new position in Orchestra BioMed during the 3rd quarter worth approximately $69,000. Catalytic Wealth RIA LLC purchased a new position in Orchestra BioMed during the 1st quarter worth approximately $117,000. Barclays PLC raised its stake in Orchestra BioMed by 281.3% during the 3rd quarter. Barclays PLC now owns 31,785 shares of the company’s stock valued at $163,000 after purchasing an additional 23,448 shares during the period. Finally, SkyView Investment Advisors LLC purchased a new stake in shares of Orchestra BioMed in the second quarter valued at $163,000. Institutional investors own 53.55% of the company’s stock.

About Orchestra BioMed

Orchestra BioMed Holdings, Inc operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.